Extracellular Vesicles in Coronary Artery Disease

Buntsma, Naomi; van der Pol, Edwin; Nieuwland, Rienk; Gąsecka, Aleksandra

doi:10.1007/978-981-99-1443-2_6

Cited by 5 publications

(3 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They play an important role in physiological and pathological conditions [ 176 ]. EVs have potential as biomarkers in the diagnosis, prognosis, and monitoring of atherosclerosis in patients and as new therapeutic targets and/or drug delivery vehicles [ 17 ]. It is worth mentioning that altered levels of EVs have been evidenced in patients suffering from atrial fibrillation [ 177 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Extracellular Vesicles in Atherosclerosis: State of the Art

Olejarz,

Sadowski,

Radoszkiewicz

2023

IJMS

View full text Add to dashboard Cite

Atherosclerosis is a chronic inflammatory disease driven by lipid accumulation in the arteries, leading to narrowing and thrombosis that causes mortality. Emerging evidence has confirmed that atherosclerosis affects younger people and is involved in the majority of deaths worldwide. EVs are associated with critical steps in atherosclerosis, cholesterol metabolism, immune response, endothelial dysfunction, vascular inflammation, and remodeling. Endothelial cell-derived EVs can interact with platelets and monocytes, thereby influencing endothelial dysfunction, atherosclerotic plaque destabilization, and the formation of thrombus. EVs are potential diagnostic and prognostic biomarkers in atherosclerosis (AS) and cardiovascular disease (CVD). Importantly, EVs derived from stem/progenitor cells are essential mediators of cardiogenesis and cardioprotection and may be used in regenerative medicine and tissue engineering.

show abstract

Section: Discussionmentioning

confidence: 99%

“…EVs can modulate phenotypes and cellular functions by regulating epigenetic alteration, transcription, and translation [ 14 , 15 ]. They have potential as biomarkers in diagnosis and prognosis as well as monitoring therapy in individuals with CVD and as new therapeutic targets and/or drug delivery vehicles [ 16 , 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

Extracellular Vesicles in Atherosclerosis: State of the Art

Olejarz,

Sadowski,

Radoszkiewicz

2023

IJMS

View full text Add to dashboard Cite

show abstract

“…EVs may represent interesting tools with different relevant applications in the CVD field. Indeed, depending on the specific cell source, EVs hold great potential for use in the diagnosis and prognosis of cardiac dysfunction, as well as novel therapeutic agents, particularly in the context of acute myocardial infarction and heart failure [ 43 , 44 ]. Their role as diagnostic elements, providing insight into disease onset and the contribution of the different cardiac cells to pathophysiological progression, has been recently demonstrated in different studies [ 45 , 46 , 47 , 48 , 49 ].…”

Section: Exploiting Evs In Cardiovascular Diseasementioning

confidence: 99%

Evolving Strategies for Extracellular Vesicles as Future Cardiac Therapeutics: From Macro- to Nano-Applications

Guerricchio,

Barile,

Bollini

2024

IJMS

View full text Add to dashboard Cite

Cardiovascular disease represents the foremost cause of mortality and morbidity worldwide, with a steadily increasing incidence due to the growth of the ageing population. Cardiac dysfunction leading to heart failure may arise from acute myocardial infarction (MI) as well as inflammatory- and cancer-related chronic cardiomyopathy. Despite pharmacological progress, effective cardiac repair represents an unmet clinical need, with heart transplantation being the only option for end-stage heart failure. The functional profiling of the biological activity of extracellular vesicles (EVs) has recently attracted increasing interest in the field of translational research for cardiac regenerative medicine. The cardioprotective and cardioactive potential of human progenitor stem/cell-derived EVs has been reported in several preclinical studies, and EVs have been suggested as promising paracrine therapy candidates for future clinical translation. Nevertheless, some compelling aspects must be properly addressed, including optimizing delivery strategies to meet patient needs and enhancing targeting specificity to the cardiac tissue. Therefore, in this review, we will discuss the most relevant aspects of the therapeutic potential of EVs released by human progenitors for cardiovascular disease, with a specific focus on the strategies that have been recently implemented to improve myocardial targeting and administration routes.

show abstract

Insight into endothelial cell-derived extracellular vesicles in cardiovascular disease: Molecular mechanisms and clinical implications

Wang,

2024

Pharmacological Research

View full text Add to dashboard Cite

Extracellular Vesicles in Coronary Artery Disease

Cited by 5 publications

References 150 publications

Extracellular Vesicles in Atherosclerosis: State of the Art

Extracellular Vesicles in Atherosclerosis: State of the Art

Evolving Strategies for Extracellular Vesicles as Future Cardiac Therapeutics: From Macro- to Nano-Applications

Insight into endothelial cell-derived extracellular vesicles in cardiovascular disease: Molecular mechanisms and clinical implications

Contact Info

Product

Resources

About